White matter lesion location correlates with disability in relapsing multiple sclerosis

被引:15
作者
Gaetano, Laura [1 ,2 ]
Magnusson, Baldur [3 ]
Kindalova, Petya [4 ]
Tomic, Davorka [3 ]
Silva, Diego [3 ]
Altermatt, Anna [1 ,5 ]
Magon, Stefano [1 ,2 ]
Mueller-Lenke, Nicole [1 ]
Radue, Ernst-Wilhelm [6 ]
Leppert, David [7 ,8 ,9 ]
Kappos, Ludwig [7 ,8 ,9 ]
Wuerfel, Jens [1 ]
Haering, Dieter A. [3 ]
Sprenger, Till [1 ,10 ]
机构
[1] Med Image Anal Ctr, Marktgasse 8, CH-4051 Basel, Switzerland
[2] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[3] Novartis Pharmaceut, Rotkreuz, Switzerland
[4] Univ Oxford, Dept Stat, Oxford, England
[5] Univ Basel, Dept Biomed Engn, Basel, Switzerland
[6] Biomed Research, Biomed Res & Training, Basel, Switzerland
[7] Univ Hosp & Univ Basel, Neurol Clin & Policlin, Dept Med, Basel, Switzerland
[8] Univ Hosp & Univ Basel, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland
[9] Univ Hosp & Univ Basel, Neurol Clin & Policlin, Dept Biomed & Biomed Engn, Basel, Switzerland
[10] DKD Helios Klin Wiesbaden, Dept Neurol, Wiesbaden, Germany
关键词
White matter lesion; multiple sclerosis and neuroinflammation; demyelination; multiple sclerosis: imaging; frontal lobe; fingolimod; disability; FINGOLIMOD; PLAQUES; ATROPHY;
D O I
10.1177/2055217320906844
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Lesion location is a prognostic factor of disease progression and disability accrual. Objective To investigate lesion formation in 11 brain regions, assess correlation between lesion location and physical and cognitive disability measures and investigate treatment effects by region. Methods In 2355 relapsing-remitting multiple sclerosis patients from the FREEDOMS and FREEDOMS II studies, we extracted T2-weighted lesion number, volume and density for each brain region; we investigated the (Spearman) correlation in lesion formation between brain regions, studied association between location and disability (at baseline and change over 2 years) using linear/logistic regression and assessed the regional effects of fingolimod versus placebo in negative binomial models. Results At baseline, the majority of lesions were found in the supratentorial brain. New and enlarging lesions over 24 months developed mainly in the frontal and sublobar regions and were substantially correlated to pre-existing lesions at baseline in the supratentorial brain (p=0.37-0.52), less so infratentorially (p=-0.04-0.23). High sublobar lesion density was consistently and significantly associated with most disability measures at baseline and worsening of physical disability over 24 months. The treatment effect of fingolimod 0.5 mg was consistent across the investigated areas and tracts. Conclusion These results highlight the role of sublobar lesions for the accrual of disability in relapsing-remitting multiple sclerosis.
引用
收藏
页数:12
相关论文
共 30 条
[1]   Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset [J].
Altermatt, Anna ;
Gaetano, Laura ;
Magon, Stefano ;
Haring, Dieter A. ;
Tomic, Davorka ;
Wuerfel, Jens ;
Radue, Ernst-Wilhelm ;
Kappos, Ludwig ;
Sprenger, Till .
BRAIN TOPOGRAPHY, 2018, 31 (05) :886-894
[2]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[3]   RELAPSING-REMITTING MULTIPLE-SCLEROSIS - SEQUENTIAL ENHANCED MR IMAGING VS CLINICAL FINDINGS IN DETERMINING DISEASE-ACTIVITY [J].
BARKHOF, F ;
SCHELTENS, P ;
FREQUIN, STFM ;
NAUTA, JJP ;
TAS, MW ;
VALK, J ;
HOMMES, OR .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1992, 159 (05) :1041-1047
[4]   The clinico-radiological paradox in multiple sclerosis revisited [J].
Barkhof, F .
CURRENT OPINION IN NEUROLOGY, 2002, 15 (03) :239-245
[5]   FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system [J].
Brinkmann, Volker .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) :1173-1182
[6]   DISTRIBUTION OF PLAQUES IN CEREBRUM IN MULTIPLE SCLEROSIS [J].
BROWNELL, B ;
HUGHES, JT .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1962, 25 (04) :315-+
[7]   Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial [J].
Calabresi, Peter A. ;
Radue, Ernst-Wilhelm ;
Goodin, Douglas ;
Jeffery, Douglas ;
Rammohan, Kottil W. ;
Reder, Anthony T. ;
Vollmer, Timothy ;
Agius, Mark A. ;
Kappos, Ludwig ;
Stites, Tracy ;
Li, Bingbing ;
Cappiello, Linda ;
von Rosenstiel, Philipp ;
Lublin, Fred D. .
LANCET NEUROLOGY, 2014, 13 (06) :545-556
[8]  
Charcot J.M. Bourneville., 1880, Lecons sur les maladies du systeme nerveux faites a la salpetriere
[9]   Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets [J].
Charil, A ;
Zijdenbos, AP ;
Taylor, J ;
Boelman, C ;
Worsley, KJ ;
Evans, AC ;
Dagher, A .
NEUROIMAGE, 2003, 19 (03) :532-544
[10]   Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis [J].
Dalton, C. M. ;
Bodini, B. ;
Samson, R. S. ;
Battaglini, M. ;
Fisniku, L. K. ;
Thompson, A. J. ;
Ciccarelli, O. ;
Miller, D. H. ;
Chard, D. T. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (03) :322-328